HORW, Switzerland, June 6, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the initiation of a clinical study with the PaQ® Insulin Delivery Device. Professor Thomas Pieber, head of the Division of Endocrinology and Metabolism at the University Hospital Graz, Austria, is conducting the study.
"This trial is an important step to demonstrate PaQ can be an effective option for the many people with type 2 diabetes who struggle with the challenges of multiple daily insulin injections," said Jim Peterson, founder and CEO, CeQur.
There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes. According to a recent publication, half of all patients requiring multiple daily injections of insulin intentionally skip doses because they consider the injections embarrassing, inconvenient, painful and/or disruptive to their daily activities. Adhering to prescribed insulin therapy regimens is important, because tight glucose control is vital to reducing the risk of long-term type 2 diabetes complications. Studies indicate that simple, continuous insulin-infusion regimens may improve glycemic control and quality of life among individuals with type 2 diabetes.
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor. PaQ is simple to use, making it easy to train patients to start and stay on therapy.
The PaQ study conducted by Professor Pieber is designed to demonstrate that individuals with type 2 diabetes can successfully use PaQ to deliver their daily insulin. Study endpoints include glycemic control, patient satisfaction and safety. CeQur expects to share initial results early next year.
"There is a tremendous need for technologies such as PaQ that make insulin administration more comfortable, simple and convenient for patients, so that they are able to maintain better control of their disease and, therefore, their health," said Professor Pieber. "PaQ was thoughtfully designed to address many of the clinical and lifestyle issues that prevent patients from receiving their insulin as needed. We are excited to launch this study to demonstrate very specifically how the PaQ performs for these patients."
About CeQur SA
CeQur® is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The company is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company's lead product candidate is the PaQ Insulin Delivery Device, a novel, wearable device that provides freedom from multiple daily injections by offering up to three days of consistent, basal insulin delivery along with bolus insulin at the push of a button. More information can be found at www.cequrcorp.com.
Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther 2010;12:627-33.
SOURCE CeQur SA